Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide

Januzzi, James L.; Xu, Jialin; Li, Jingwei; Shaw, Wayne; Oh, Richard; Pfeifer, Michael; Butler, Javed; Sattar, Naveed; Mahaffey, Kenneth W.; Neal, Bruce; Hansen, Michael K.

doi:10.1016/j.jacc.2020.09.004

Cited by 67 publications

(53 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16,17 In daily clinical practice, the assessment of a single marker that allows to identify those at highest risk seems attractive. In this study, as in others, [18][19][20][21][22] NT-proBNP levels above 125 pg/ml were strongly associated with adverse outcomes in T2DM patients. Given the high negative predictive value of NT-proBNP at a cutoff level of 125mg/dl, 21,22 initial assessment of NT-proBNP could serve as a rst-line screening tool that allows to safely and effectively rule out increased CV risk, while higher values would require further evaluation.…”

Section: Discussionsupporting

confidence: 84%

“…39 A recent observation from the CANVAS (Canagli ozin Cardiovascular Assessment Study) study has shown that canagli ozin treatment in T2DM patients with NT-proBNP levels above 125 pg/ml achieved greater absolute risk reductions in event rates compared to those with lower concentrations. 18 In general, screening for high-risk individuals may only be appropriate when effective treatments are available. The high prevalence of modi able risk factors among individuals with diabetes but also the recent emerge of new therapies with favorable effects on CVD outcome such as sodium-glucose cotransporter-2 inhibitors underscore the importance of identifying those who would most probably bene t from initiation or optimizing treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus

Prausmüller

Resl

Arfsten

et al. 2021

Preprint

View full text Add to dashboard Cite

Background. Recently, the European Society of Cardiology (ESC) and European Association for the Society of Diabetes (EASD) introduced a new cardiovascular disease (CVD) risk stratification model to aid further treatment decisions in individuals with diabetes. Our study aimed to investigate the prognostic performance of the ESC/EASD risk model in comparison to the Systematic COronary Risk Evaluation (SCORE) risk model and NT-proBNP in an unselected cohort of type 2 diabetes mellitus (T2DM).Methods & Results. A total of 1690 T2DM patients with a 10-year follow up for fatal CVD and all-cause death and a 5-year follow up for CVD and all-cause hospitalizations were analyzed. According to ESC/EASD risk criteria 25 (1.5%) patients were classified as moderate, 252 (14.9%) high, 1125 (66.6%) very high risk and 288 (17.0%) were not classifiable. Both, NT-proBNP and SCORE risk model were associated with 10-year CVD and all-cause death and 5-year CVD and all-cause hospitalizations while the ESC/EASD model was only associated with 10-year all-cause death and 5-year all-cause hospitalizations. NT-proBNP and SCORE showed significantly higher C-indices than the ESC/EASD risk model for CVD death [0.80 vs 0.53, p<0.001; 0.64 vs 0.53, p=0.001] and all-cause death [0.73, 0.66 vs 0.52, p<0.001 for both].The performance of SCORE improved in a subgroup without CVD aged 40-64 years compared to the unselected cohort, while NT-proBNP performance was robust across all groups.Conclusion. The new introduced ESC/EASD risk stratification model performed limited compared to SCORE and single NT-proBNP assessment for predicting 10-year CVD and all-cause fatal events in individuals with T2DM.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus

Prausmüller

Resl

Arfsten

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…16,17 In daily clinical practice, the assessment of a single marker that allows to identify those at highest risk seems attractive. In this study, as in others, [18][19][20][21][22] NT-proBNP levels above 125 pg/ml were strongly associated with adverse outcomes in T2DM patients. Given the high negative predictive value of NT-proBNP at a cutoff level of 125mg/dl, 21,22 initial assessment of NT-proBNP could serve as a rst-line screening tool that allows to safely and effectively rule increased CV risk, while higher values would require further evaluation.…”

Section: Discussionsupporting

confidence: 84%

“…38 A recent observation from the CANVAS (Canagli ozin Cardiovascular Assessment Study) study has shown that canagli ozin treatment in T2DM patients with NT-proBNP levels above 125 pg/ml achieved greater absolute risk reductions in event rates compared to those with lower concentrations. 18 In general, screening for high-risk individuals may only be appropriate when effective treatments are available. The high prevalence of modi able risk factors among individuals with diabetes but also the recent emerge of new therapies with favorable effects on CVD outcome such as sodium-glucose cotransporter-2 inhibitors underscore the importance of identifying those who would most probably bene t from initiation or optimizing treatment.…”

Section: Discussionmentioning

confidence: 99%

“…4 The prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for CVD outcomes in patients with diabetes has been demonstrated and was con rmed in numerous studies. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] Nonetheless, the new guidelines do not recommend routine assessment of circulating biomarkers for CVD risk estimation in diabetic patients. 3…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Performance of the recommended ESC/EASD cardiovascular risk stratification model and SCORE in comparison to NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus

Prausmüller

Resl

Arfsten

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Recently, the European Society of Cardiology (ESC) and European Association for the Society of Diabetes (EASD) introduced a new cardiovascular disease (CVD) risk stratification model to aid further treatment decisions in individuals with diabetes. Our study aimed to investigate the prognostic performance of the ESC/EASD risk model and the Systematic COronary Risk Evaluation (SCORE) in comparison to NT-proBNP in an unselected cohort of type 2 diabetes mellitus (T2DM).Methods & Results. A total of 1690 T2DM patients with a 10-year follow up for fatal CVD and all-cause death and a 5-year follow up for CVD and all-cause hospitalizations were analyzed. According to ESC/EASD risk criteria 25 (1.5%) patients were classified as moderate, 252 (14.9%) high, 1125 (66.6%) very high risk and 288 (17.0%) were not classifiable. Both, NT-proBNP and SCORE risk model were associated with 10-year CVD and all-cause death and 5-year CVD and all-cause hospitalizations while the ESC/EASD model was only associated with 10-year all-cause death and 5-year all-cause hospitalizations. NT-proBNP showed significantly higher C-indices than the ESC/EASD and SCORE risk model for CVD death [0.80 vs 0.53 vs 0.64, p<0.001] and all-cause death [0.73 vs 0.52 vs 0.66, p<0.001]. The performance of SCORE improved in a subgroup without CVD aged 40-64 years compared to the unselected cohort, while NT-proBNP performance was robust across all groups.Conclusion. The new introduced ESC/EASD risk stratification model performed limited compared to SCORE and single NT-proBNP assessment for predicting 10-year CVD and all-cause fatal events in individuals with T2DM.

show abstract

Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events

et al. 2023

View full text Add to dashboard Cite

In modern cardiology, sodium-glucose cotransporter 2 (SGLT2) inhibitors are critical components of heart failure (HF) treatment algorithms and exert their effects primarily by preventing glucose reabsorption and facilitating its urinary excretion. The objective was to systematically review randomized controlled trials (RCTs) assessing the effects of SGLT2 inhibitors, particularly canagliflozin, empagliflozin, dapagliflozin, ertugliflozin, sotagliflozin (dual SGLT inhibitor), and their use in HF. Systematic searches of PubMed/Medline, The Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials. gov databases were performed. There were no restrictions imposed on the date and status of publication; however, there were restrictions on language for the searched studies. A total of 1139 records were identified in the bibliographic searches from both databases and the register of choice for this systematic review. Following duplicate removal, screening for titles and abstracts, and thorough assessment of full-text articles, 12 RCTs met the inclusion criteria. Altogether, 83 878 patients were included in this review. Among the included studies, two RCTs, with six respective reports, investigated canagliflozin, four RCTs with 13 derived reports investigated dapagliflozin, three RCTs with 12 separate reports studied the effects of empagliflozin, one RCT and its three respective reports assessed ertugliflozin's effects, and two RCTs with one added report investigated the dual inhibitor sotagliflozin. Pooled meta-analytic effects of SGLT2 inhibitors were as follows: on atrial fibrillation odds ratio (OR) = 0.

show abstract

Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide

Cited by 67 publications

References 23 publications

Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus

Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus

Performance of the recommended ESC/EASD cardiovascular risk stratification model and SCORE in comparison to NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus

Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events

Contact Info

Product

Resources

About